AMPH Amphastar Pharmaceuticals Inc
Price (delayed)
$26.28
Market cap
$1.25B
P/E Ratio
7.99
Dividend/share
N/A
EPS
$3.29
Enterprise value
$1.75B
Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active
Highlights
The stock's P/E is 90% less than its 5-year quarterly average of 84.1 and 38% less than its last 4 quarters average of 12.9
The net income has grown by 16% YoY
Amphastar Pharmaceuticals's quick ratio has increased by 25% YoY but it has decreased by 16% QoQ
The company's gross profit rose by 6% YoY but it fell by 2.5% QoQ
Amphastar Pharmaceuticals's gross margin has decreased by 6% YoY and by 3.6% QoQ
AMPH's debt is up by 4.3% year-on-year and by 3.3% since the previous quarter
Key stats
What are the main financial stats of AMPH
Market
Valuations
Earnings
Shares outstanding
47.65M
Market cap
$1.25B
Enterprise value
$1.75B
Price to earnings (P/E)
7.99
Price to book (P/B)
1.73
Price to sales (P/S)
1.74
EV/EBIT
7.98
EV/EBITDA
6.33
EV/Sales
2.39
Revenue
$731.97M
Gross profit
$373.86M
Operating income
$205.42M
Net income
$159.52M
EBIT
$219.53M
EBITDA
$276.74M
Free cash flow
$172.35M
Per share
Balance sheet
Liquidity
EPS
$3.29
EPS diluted
$3.06
Free cash flow per share
$3.56
Book value per share
$15.23
Revenue per share
$15.11
TBVPS
$20.38
Total assets
$1.58B
Total liabilities
$845.17M
Debt
$650.55M
Equity
$732.3M
Working capital
$360.31M
Debt to equity
0.89
Current ratio
3.07
Quick ratio
2.07
Net debt/EBITDA
1.8
Margins
Efficiency
Dividend
EBITDA margin
37.8%
Gross margin
51.1%
Net margin
21.8%
Operating margin
28.1%
Return on assets
10.3%
Return on equity
22.4%
Return on invested capital
18.1%
Return on capital employed
15.6%
Return on sales
30%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMPH stock price
How has the Amphastar Pharmaceuticals stock price performed over time
Intraday
-3.84%
1 week
-6.34%
1 month
-17.41%
1 year
-40.48%
YTD
-29.22%
QTD
-29.22%
Financial performance
How have Amphastar Pharmaceuticals's revenue and profit performed over time
Revenue
$731.97M
Gross profit
$373.86M
Operating income
$205.42M
Net income
$159.52M
Gross margin
51.1%
Net margin
21.8%
The net income has grown by 16% YoY
Amphastar Pharmaceuticals's revenue has increased by 14% YoY
AMPH's operating margin is down by 8% year-on-year and by 5% since the previous quarter
The company's gross profit rose by 6% YoY but it fell by 2.5% QoQ
Growth
What is Amphastar Pharmaceuticals's growth rate over time
Valuation
What is Amphastar Pharmaceuticals stock price valuation
P/E
7.99
P/B
1.73
P/S
1.74
EV/EBIT
7.98
EV/EBITDA
6.33
EV/Sales
2.39
The stock's P/E is 90% less than its 5-year quarterly average of 84.1 and 38% less than its last 4 quarters average of 12.9
The EPS has grown by 15% YoY
The price to book (P/B) is 40% lower than the 5-year quarterly average of 2.9 and 40% lower than the last 4 quarters average of 2.9
Amphastar Pharmaceuticals's equity has increased by 15% YoY
AMPH's price to sales (P/S) is 44% less than its 5-year quarterly average of 3.1 and 40% less than its last 4 quarters average of 2.9
Amphastar Pharmaceuticals's revenue has increased by 14% YoY
Efficiency
How efficient is Amphastar Pharmaceuticals business performance
The ROIC is down by 16% year-on-year and by 3.2% since the previous quarter
The company's return on assets fell by 2.8% YoY
The ROE has contracted by 3.4% YoY and by 2.2% from the previous quarter
Dividends
What is AMPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMPH.
Financial health
How did Amphastar Pharmaceuticals financials performed over time
The total assets is 87% greater than the total liabilities
Amphastar Pharmaceuticals's current ratio has increased by 41% YoY but it has decreased by 10% from the previous quarter
Amphastar Pharmaceuticals's quick ratio has increased by 25% YoY but it has decreased by 16% QoQ
AMPH's debt is 11% smaller than its equity
Amphastar Pharmaceuticals's equity has increased by 15% YoY
Amphastar Pharmaceuticals's debt to equity has decreased by 9% YoY but it has increased by 2.3% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.